Philip Davis Marsden
Texto completo disponível apenas em PDF.
Full text available only in PDF format.
REFERENCES
1. Anonymous. The leishmaniases. World Health Organization Technical Report Series n.° 701, Geneva, 1984. [ Links ]
2. Berman JD. In vitro susceptibility of antimony resistant Leishmania to altemative drugs. Journal of Infectious Diseases 145: 279, 1982. [ Links ]
3. Beveridge E. Chemotherapy of leishmaniasis. In: Schnitzer RJ, Hawking F (ed) Experimental chemotherapy, vol. 1, Academic Press, New York, 1963. [ Links ]
4. Brahmachari PN, Maiti CR, Kor CC. Agranulocytosis following antimony therapy in kala-azar. Journal Indian Medical Association 25: 408-410, 1955. [ Links ]
5. Bryceson ADM. Therapy in man. In: Peters W, Killick Kendrick R (ed) The leishmaniasis in biology and medicine, Academic Press, London, in press. [ Links ]
6. Carini A. Três casos de leishmaniose. Archivos da Sociedade de Medicina e Cirurgia de São Paulo 5: 8-9, 1914. [ Links ]
7. Castro CN, Costa JML, Sampaio RNR, Marsden PD. Unusual side effects following pentavalent antimonial therapy. Revista da Sociedade Brasileira de Medicina Tropical, in press. [ Links ]
8. Castro RM. Tratamento da leishmaniose tegumentar americana. Anais Brasileiro de Dermatologia 55: 87-89, 1980. [ Links ]
9. Chance ML, New RRC. The use of liposomés in the treatment of experimental cutaneous and visceral leishmaniasis. In: VandeBossche(ed)The Host Parasite Interplay, p. 659. Elsevier/North Holland Biomedical Press, Amsterdam, 1980. [ Links ]
10. Chapman WL, Hanson WL, Waits VB, Kinnamon K.E. Antileishmanial activity of selected compounds in dogs experimentally infected with Leishmania donovani. Revista do Instituto de Medicina Tropical de São Paulo 21: 189-193, 1979. [ Links ]
11. Chapman WL, Hanson WL, Alving CR, Hendricks LD. Antileishmanial activity of liposome encapsulated meglumine antimonate in the dog. American Journal of Veterinary Research 45: 1028-1030, 1984. [ Links ]
12. Chulay J. Clinical pharmacokinetics of currently used compounds and their side effects. Informal meeting on Chemotherapy of Visceral Leishmaniasis. Mimeographed document. Nairobi, 1982. [ Links ]
13. Chulay JD, Oster CN, McGreevy PB, Kreutzer RD, Hendricks LD. American cutaneous leishmaniasis. Clinical presentation and problems of patient management Journal of Infectious Disease, in press. [ Links ]
14. Chulay JD, Spencer HC, Mugambi M. Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (Sodium stibogluconate). American Journal of Tropical Medicine and Hygiene 34: 702-709, 1985. [ Links ]
15. Corrêa A, Elizabetsky M. Ação de antimoniato de N- methyl glucamina sobre as lesões mucosas de leishmaniose tegumentar americana. Publicações Médicas de São Paulo 22: 13-21, 1952. [ Links ]
16. Costa JML, Marsden PD, Llanos-Cuentas EA, Netto EM, Carvalho EM, Barrai A, Rosa AC, Cuba CC, Magalhães AV, Barreto AC. Disseminated cutaneous leishmaniasis in a field clinic. Report of 8 cases. Journal of Tropical Medicine and Hygiene, in press. [ Links ]
17. Cuba Cuba CA, Marsden PD, Barreto AC, Roitman I, Vexenat A, De Lima LMP, De Sá MHP. Identification of human stocks of Leishmania spp. isolated from patients with mucocutaneous leishmaniasis in Três Braços, Bahia, Brazil. Transactions of the Royal Society of Tropical Medicine and Hygiene 78: 708-710, 1984. [ Links ]
18. Cuce LC, Freitas THP, Oliveira ZNP, Sampaio SAP. Tratamento da leishmaniose tegumentar americana pelo antimônio pentavalente (esquema rápido). Anais Brasileiros de Dermatologia 57:107-108, 1982. [ Links ]
19. Di Christina G, Caronia G. Sulla terapia delia leishmaniosi interna. Bulletin de la Sociétè de Pathologie Éxotique 8: 63-66, 1915. [ Links ]
20. Dietze R, Araújo RC, Lima MLR, Vexenat JA, Marsden PD, Barreto AC. Ensaio terapêutico com glucantime em sagüis (Callithrix jacchus) infectados com uma cepa de Leishmania donovani aparentemente resistente ao tratamento. Revista da Sociedade Brasileira de Medicina Tropical 18: 39-42, 1985. [ Links ]
21. Durand P, Benmussa S,Caruana M. Traitement du kala- azar par un noveau composé stibié 2, 168 RP (premiers résultats). Bulletin Sociétè Medicine Hôpital Paris 62: 399-409, 1946. [ Links ]
22. Dutra e Silva O. Sobre a leishmaniose tegumentar e seu tratamento. Memórias do Instituto Oswaldo Cruz 7: 213-248, 1915. [ Links ] 23. Falcão EC, Opera Omnia de Gaspar Vianna. Empresa Gráfica da Revista dos Tribunais, São Paulo, 1962. [ Links ]
24. Furtado TA. An appraisal of chemotherapy of American leishmaniasis. Dermatologia Ibérica Latino-Americana 3: 257-268, 1968. [ Links ]
25. Furtado T, Vieira JBF. Geografia da leishmaniose tegumentar americana no Brasil. Anais Brasileiro de Dermatologia 57: 135-140, 1982. [ Links ]
26. Gagliardi ART, Veiga JPR, Rosa TT, Marsden PD. Pentavalent antimony inhibition of water transport by the toad bladder. Brazilian Journal of Medical and Biological Research, in press. [ Links ]
27. Gelhorn A, Van Dyke HB. The correlation between distribution of antimony in tissues and chemotherapeutic effect in experimental leishmaniasis. Journal of Pharmacology and Experimental Therapeutics 88: 162-172, 1946. [ Links ]
28. Gelhorn A, Tupikova NA, Van Dyke HB. The tissue distribution and excretion of four organic antimonials after single or repeated administration to normal hamsters. Journal of Pharmacology and Experimental Therapeutics 87: 169-180, 1945. [ Links ]
29. Goldfrey DG. Molecular biochemical characterization of human parasites. In: Gilles HM (ed) Recent Advance in Tropical Medicine. Churchill Livingstone, Edinburgh, p. 289-319, 1984. [ Links ]
30. Goodwin LG, Page JE. A study of the excretion of organic antimonials using a polargraphic procedure. Biochemical Journal 37: 198-209, 1943. [ Links ]
31. Goodwin LG. The toxicity and trypanocidal activity of some organic antimonials. Journal of Pharmacology and Experimental Therapeutics 81: 224-234, 1944. [ Links ]
32. Goodwin LG. Commentary. In: Trypanosomiasis and Leishmaniasis. Ciba Foundation Symposium 20. Elsevier, North Holland, Amsterdam, p. 331, 1974. [ Links ]
33. Hanson WL, Waits VB. Relative insensitivity of a Kenyan strain of Leishmania donovani to pentavalent antimony therapy in hamster. Journal of Parasitology 69: 446-447, 1983. [ Links ]
34. Jolliffe DS. Nephrotoxicity of pentavalent antimonials. Lancet 1: 584, 1985. [ Links ]
35. Kager PA, Rees PH. Clinical aspects of kala-azar in Kenya ICG Printing Dordrecht, 1983. [ Links ]
36. Kikuth W, Schmidt H. Contribution to the progress of antimony therapy of kala-azar. Chinese Medical Journal 52: 425-432, 1937. [ Links ]
37. Llanos-Cuentas EA, Marsden PD, Lago EL, Barreto AC, Cuba CC, Johnson WD. Leishmaniose muco- cutánea humana em Três Braços, Bahia. Uma área de transmissão de Leishmania braziliensis braziliensis. II Doença cutânea: apresentação e evolução. Revista da Sociedade Brasileira de Medicina Tropical 17:169-177, 1984. [ Links ]
38. Marsden PD. Selective primary health care: strategies for control of disease in the developing world. XIV Leishmaniasis. Reviews of Infectious Disease 6: 736- 744, 1984. [ Links ]
39. Marsden PD. New light on pentavalent antimonials in the treatment of leishmaniasis. Revista da Sociedade Brasileira de Medicina Tropical 16: 172-174, 1983. [ Links ]
40. Marsden PD, Llanos-Cuentas EA, Lago EL, Cuba CC, Barreto AC, Costa JM, Jones TC. Human muco- cutaneous leishmaniasis in Três Braços, Bahia-Brazil. An area of Leishmania braziliensis braziliensis transmission. III Mucosal disease: presentation and initial evolution. Revista da Sociedade Brasileira de Medicina Tropical 17: 179-186, 1984. [ Links ]
41. Marsden PD, Sampaio RNR, Carvalho EM, Veiga JPR, Costa JLM, Llanos-Cuentas EA. High continuous antimony therapy in two patients with unresponsive mucosal leishmaniasis. American Journal of Tropical Medicine and Hygiene, 34: 710-713, 1985. [ Links ]
42. McGreevy PB, Marsden PD. American trypanosomiasis and leishmaniasis in the chemotherapy of parasitic diseases. Ed. Campbell W.C., Rew R. S., PlenumPress, in press. Moreira ESA. Ação do antimoniato de N-metilglucamina sobre formas promastigotas de Leishmania. Masters thesis, Universidade Federal de Minas Gerais, Belo Horizonte, 1984. [ Links ]
44. Muller RH, Valera M, Carrasco H, Fuenmayor A, Benedetti JR, Torrealba W, Mendonza E. Valoracion electrocardiografica de la cardiotoxicidad del antimoniato de N-metil glucamina(RGlucantime). Arquivos do Instituto de Cardiologia Mexicana 52: 155-9, 1982. [ Links ]
45. Napier LE, Muir E. Kala-azar. London, Oxford University Press, 1923. [ Links ]
46. Napier L. E. Chaudhui R, Rai Chaudhui M. N. A stable solution of antimony for the treatment of kala-azar. Indian Medical Gazette 72: 462-465, 1937. [ Links ]
47. Nelson DJ, Lafon SW, Tuttle JV, Miller WH, Miller RL, Krenitsky TA, Elion GB, Berens RL, Marr JJ. Allopurinol riboside as an antileishmanial agent. Journal of Biological Chemistry 254: 11544-11549, 1979. [ Links ]
48. Netto EM, Tada MS, Golightly L, Kalter DC, Lago E, Barreto AC, Marsden, PD. Conceitos de uma população local a respeito da leishmaniose mucocutânea em uma área endêmica. Revista da Sociedade Brasileira de Medicina Tropical 18: 33-37, 1985. [ Links ]
49. Neves J. Tratamento da leishmaniose visceral americana pelo antimoniato de N’metil glucamina. Tese, Universidade Federal de Minas Gerais, Belo Horizonte, 1963. [ Links ]
50. Oster CN, Chulay JD, Hendricks LD, Pamplin CL, Ballow WR, Berman JD, Takafuji EJ, Tramont EC, Canfield CJ. American cutaneous leishmaniasis: a comparision of three sodium stibogluconate treatment schedules. American Journal of Tropical Medicine and Hygiene 34: 856-860, 1985. [ Links ]
51. Otto GF, Maren TH, Brown HW. Blood leveis and excretion rates of antimony in persons receiving trivalent e pentavalent antimonials. American Journal of Hygiene 46: 193-211, 1947. [ Links ]
52. Pablos Gallego JM, Torres AC, Almagro M, De Puerta S, Garrido PL, Morales MG, Esquivias JJ. Kala-azar y anemia hemolitica autoimmune. A propósito de un caso de evolución fatal por hepatotoxicidad del antimoniato de N’metil glucamina. Revista Clinica Espanola 164: 417-420, 1982. [ Links ]
53. Panayotatou A. Infantile kala-azar: a case cured at Alexandria by a new method. British Journal of Childhood Diseases 26: 112-115, 1929. [ Links ]
54. Pessoa SB, Barreto MP. Leishmaniose tegumentar americana. Imprensa Nacional, Rio de Janeiro. 1948. [ Links ]
55. Peters W. The treatment of kala-azar – new approaches to an old problem. Indian Journal of Medical Research (Supplement) 73: 1-18, 1981. [ Links ]
56. Pratt DM, Bennett e, David JR. Monoclonal antibodies that distinguish subspecies of Leishmania braziliensis. Journal of Immunology 129: 926-927, 1982. [ Links ]
57. Raju S, Schneider J. Traitement d’une leishmaniose cutanée por l’antimoniate de N-methyl glucantime (2168 RP). Bulletin Sociétè Française Dermatologie et Syphilis 2: 38, 1947. [ Links ]
58. Rao LS, Hardy JG, Wilson CG. Tissue distribution and rate of free and liposome – encapsulated (125 Sb) sodium stibogluconate by gamma scintigraphy. International Journal of Pharmaceutics 17: 283-290, 1983. [ Links ]
59. Rees, PH, Kager PA, Keating MI, Hockmeyer WT. Renal clearance of pentavalent antimony (sodium stibogluconate). Lancet 2: 226-229, 1980. [ Links ]
60. Rocha RAA, Sampaio RN, Guerra M, Magalhães A, Cuba CC, Barreto AC, Marsden PD. Apparent glucantime failure in five patients with mucocutaneous leishmaniasis. Journal of Tropical Medicine and Hygiene 83: 131-139, 1980. [ Links ]
61. Sampaio RNR, Rocha RAA, Marsden PD, Cuba CC, Barreto AC. Leishmaniose tegumentar americana. Casuística do Hospital Escola da UnB. Anais Brasileiro de Dermatologia 55: 69-76, 1980. [ Links ]
62. Sampaio RNR. Tratamento hospitalar da leishmaniose cutâneo mucosa. Master’s thesis, Universidade Federal de Minas Gerais, Belo Horizonte, 1984. [ Links ]
63. Sampaio RNR, Sampaio JHD, Marsden PD. Pentavalent antimonial treatment in mucosal leishmaniasis. Lancet 1:.1097, 1985. [ Links ]
64. Schimdt H. An advance in the therapeutics of pentavalent antimony: solustibosan (sodium antimony gluconate). Journal of Tropical Medicine and Hygiene 53: 95-102, 1950. [ Links ]
65. Solano AE, Hidalgo HH, Zeledon RA. Tratamiento intralesional exitoso de la leishmaniasis por Leishmania braziliensis panamensis com glucantime. Medicina Cutis ILA 12: 19-24, 1984. [ Links ]
66. Soto JM, Urbina A, Convit J. Comunication preliminar sobre toxicidad cardiaca de antimonial pentavalente. Revista Venezoelana de Sanidade e Assistência Social 39: 269-278, 1974. [ Links ]
67. Steck EA. The leishmaniasis. In: Jucker E (ed) Progress in drug research. Birkhàuser Verlag, Basel, p. 289-351, 1974. [ Links ]
68. Teixeira R. Experiências vividas com a leishmaniose visceral. 1954-1980. (Aspectos epidemiológicos, sorológicos e evolutivos). Doctoral thesis, Universidade Federal da Bahia, Salvador, 1980. [ Links ]
69. Terra F. Leishmaniose tegumentaire au Brèsil. Boletim da Sociedade Brasileira de Dermatologia 2-3: 58-67, 1913. [ Links ]
70. Veiga JPR, WolfFER, Sampaio RN, Marsden PD. Renal tubular dysfunction in patients with mucocutaneous leishmaniasis treated with pentavalent antimonials. Lancet 2: 569, 1983. [ Links ]
71. Veiga JPR, Rosa TT, Kimachi T, Wolf ER, Sampaio RN, Gagliardi RT, Juqueira LF, Costa JML, Marsden PD. Função renal em pacientes com leishmaniose muco- cutânea tratados com antimoniais pentavalentes. Revista do Instituto de Medicina Tropical de São Paulo, in press. [ Links ]
72. Vianna G. Tratamento da leishmaniose tegumentar por injeções intravenosas de tartar emético. Anais do 7oCongresso Brasileiro de Medicina e Cirurgia 4:426-428, 1912. [ Links ]
73. Vianna G. Sobre o tratamento de leishmaniose tegumentar. Anais Paulista de Medicina e Cirurgia 2: 167- 169, 1914. [ Links ]
Recebido para publicação em 23/5/85.
Núcleo de Medicina Tropical e Nutrição, Universidade de Brasília – 70910 Brasília-DF, Brasil.
The main support over the years for these clinical studies has been from a United States Public Service Grant(AI 16282), administered by the Department of International Medicine, Comell Medical College, New York.
